Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹63.48Prev. Close
₹52.9Turnover(Lac.)
₹1.57Day's High
₹63.48Day's Low
₹63.4852 Week's High
₹52.952 Week's Low
₹33.35Book Value
₹24.06Face Value
₹10Mkt Cap (₹ Cr.)
29.02P/E
59.89EPS
1.06Divi. Yield
031 Jul 2023
12:00 AM
AGM
Announcement Date: 31 Jul, 2023
4 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
31 Jul 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 2.52 | 3.55 | 3.55 | 3.54 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 5.62 | 4.14 | 3.75 | 3.29 |
Net Worth | 8.14 | 7.69 | 7.3 | 6.83 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 6.11 | 7.53 | 7.95 | 8.04 |
yoy growth (%) | -18.88 | -5.29 | -1.1 | -0.59 |
Raw materials | -2.18 | -2.74 | -2.7 | -2.94 |
As % of sales | 35.72 | 36.4 | 33.96 | 36.58 |
Employee costs | -2.5 | -3.52 | -3.39 | -3.13 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0.24 | 0.17 | 0.15 | 0.11 |
Depreciation | -0.19 | -0.19 | -0.22 | -0.26 |
Tax paid | -0.03 | -0.04 | 0.07 | 0.02 |
Working capital | 1.08 | 0.76 | -0.11 | -0.08 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -18.88 | -5.29 | -1.1 | -0.59 |
Op profit growth | 9.63 | -15.59 | -12.37 | -9.23 |
EBIT growth | 36.58 | 3.28 | -0.36 | -11.69 |
Net profit growth | 59.12 | -43.44 | 63.45 | 49.18 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,527.45 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,569.85 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.85 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,105.7 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,493.4 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director & Company Secretary
L S Mani
Whole-time Director
N K Menon
Independent Director
Vasant K Bhat
Independent Director
A Krishna Kumar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Colinz Laboratories Ltd
Summary
Colinz Laboratories Limited, was incorporated as a Private Limited Company in 1986. The Company got converted into Public Limited Company in 1995, which however started their manufacturing and marketing activities in 1995. The Company manufactures a wide variety of pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams etc. The Company is having certain specialized products for Gynaecology, Cardiology, Gastroentrology etc. Since, the Company falls under the MSME sector, it established reputation as a quality supplier of medicines in the domestic market, wherever the Company has operation.Apart from this, the Company has a WHO compliant plant at Sinnar. Apart from a modern plant, it has its own well equipped quality control laboratory. The technical team is headed by a Vice President (works), Plant Manager & Production Manager etc. They are highly qualified and FDA approved expert staff with over two decades of experience in manufacturing and development of a number of products for various therapeutic segments. The Companys products are enjoying a good Brand image, particularly among gynaecologists. The Company has potential to grow considering the fact that it is yet to open up its marketing operations in many states of the country, which is kept on hold due to general economic situation.
Read More
What is the Colinz Laboratories Ltd share price today?
The Colinz Laboratories Ltd shares price on nse is Rs.₹63.48 today.
What is the Market Cap of Colinz Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Colinz Laboratories Ltd is ₹29.02 Cr. as of 03 Jul ‘24
What is the PE and PB ratio of Colinz Laboratories Ltd?
The PE and PB ratios of Colinz Laboratories Ltd is 59.89 and 2.64 as of 03 Jul ‘24
What is the 52 Week High and Low of Colinz Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Colinz Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Colinz Laboratories Ltd is ₹33.35 and ₹52.9 as of 03 Jul ‘24
What is the CAGR of Colinz Laboratories Ltd?
Colinz Laboratories Ltd's CAGR for 5 Years at 43.51%, 3 Years at 26.15%, 1 Year at 51.36%, 6 Month at 31.27%, 3 Month at 30.14% and 1 Month at 35.02%.
What is the shareholding pattern of Colinz Laboratories Ltd?
The shareholding pattern of Colinz Laboratories Ltd is as follows:
Promoters - 66.00 %
Institutions - 0.00 %
Public - 34.00 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
